LitCovid-sentences  

PMC:7784824 / 12468-16463 JSONTXT 2 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T126 0-7 Sentence denotes Results
T127 8-110 Sentence denotes Sensitivity on day 2–7 after symptom onset ranged from 0% to 57% for IgM/A and from 0% to 71% for IgG.
T128 111-216 Sentence denotes Sensitivity on day 8–18 after symptom onset ranged from 50% to 94% for IgM/A and from 81% to 94% for IgG.
T129 217-420 Sentence denotes If IgA/M and IgG were both available, the combined IgM/A and IgG sensitivity result was consistently higher than the separate interpretation (range 14–71% on day 2–7 and 88–94% on day 8–18; see Table 2).
T130 421-429 Sentence denotes Table 2.
T131 430-476 Sentence denotes Sensitivity and specificity of all test assays
T132 477-570 Sentence denotes Test Assay Sensitivity day 2–7 Sensitivity day 8–18 Overall sensitivity day 2-d18 Specificity
T133 571-641 Sentence denotes   IgM* IgG IgM* + IgG IgM* IgG IgM* + IgG IgM* IgG IgM* + IgG IgM* IgG
T134 642-682 Sentence denotes Point-of-care test                      
T135 683-797 Sentence denotes Corona Virus (COVID-19) Combined IgM/IgG Rapid test (Sol scientifics) 57% 14% 57% 94% 88% 94% 83% 65% 83% 79% 100%
T136 798-894 Sentence denotes COVID-19 IgG/IgM Rapid test Cassette (Orient Gene) 43% 29% 43% 94% 88% 94% 78% 70% 78% 100% 100%
T137 895-938 Sentence denotes SARS-CoV-2 Ab rapid test (Wantai) n.a. n.a.
T138 939-952 Sentence denotes 43% n.a. n.a.
T139 953-966 Sentence denotes 94% n.a. n.a.
T140 967-975 Sentence denotes 78% n.a.
T141 976-980 Sentence denotes 100%
T142 981-1073 Sentence denotes COVID-19 IgG/IgM RAPID TEST (PRIMA PROFESSIONAL) 0% 29% 29% 50% 81% 88% 35% 65% 70% 95% 100%
T143 1074-1182 Sentence denotes Diagnostic Kit for IgG/IgM Antibody to SARS-CoV-2 (WIZ BIOTECH) 14% 14% 14% 94% 94% 94% 70% 70% 70% 95% 100%
T144 1183-1246 Sentence denotes Enzyme-Linked Immunosorbent Assay (ELISA)                      
T145 1247-1320 Sentence denotes Anti-SARS-CoV-2 (EUROIMMUN)* 57% 29% 57% 94% 88% 94% 83% 70% 83% 95% 100%
T146 1321-1413 Sentence denotes Novel Coronavirus COVID-19 (Epitope Diagnostics) 29% 71% 71% 69% 94% 94% 57% 87% 87% 95% 89%
T147 1414-1507 Sentence denotes SARS-CoV-2 IgG ELISA Kit (Creative Diagnostics) 29% 14% 29% 94% 88% 94% 74% 65% 74% 100% 100%
T148 1508-1561 Sentence denotes Human Anti-2019 nCoV(N) IgG ELISA kit (Finetest) n.a.
T149 1562-1575 Sentence denotes 29% n.a. n.a.
T150 1576-1589 Sentence denotes 88% n.a. n.a.
T151 1590-1603 Sentence denotes 70% n.a. n.a.
T152 1604-1607 Sentence denotes 83%
T153 1608-1677 Sentence denotes Chemiluminescent microparticle immunoassay (CMIA)                    
T154 1678-1706 Sentence denotes SARS-CoV-2 IgG (Abbott) n.a.
T155 1707-1720 Sentence denotes 29% n.a. n.a.
T156 1721-1734 Sentence denotes 88% n.a. n.a.
T157 1735-1748 Sentence denotes 70% n.a. n.a.
T158 1749-1753 Sentence denotes 100%
T159 1754-1812 Sentence denotes Chemiluminescence immunoassay (CLIA)                      
T160 1813-1857 Sentence denotes Liaison SARS-CoV-2 S1/S2 IgG (DiaSorin) n.a.
T161 1858-1870 Sentence denotes 0% n.a. n.a.
T162 1871-1884 Sentence denotes 81% n.a. n.a.
T163 1885-1898 Sentence denotes 59% n.a. n.a.
T164 1899-1903 Sentence denotes 100%
T165 1904-1933 Sentence denotes Anti-SARS-CoV-2 (EUROIMMUN)*:
T166 1934-1974 Sentence denotes IgA instead of IgM; n.a.: not applicable
T167 1975-2062 Sentence denotes Overall the specificity for SARS-CoV-2 IgG was excellent (100%) for all but two assays:
T168 2063-2320 Sentence denotes The Novel Coronavirus COVID-19 (Epitope Diagnostics) kit showed cross reaction with Toxo IgM+ sample and one pre-pandemic sample and the Human Anti-2019 nCoV(N) IgG ELISA kit (Finetest) showed cross reaction with Toxo IgM+ sample and 2 pre-pandemic samples.
T169 2321-2479 Sentence denotes For IgM, only two assays showed a specificity of 100%: COVID-19 IgG/IgM Rapid test Cassette (Orient Gene) and SARS-CoV-2 IgG ELISA Kit (Creative Diagnostics).
T170 2480-3082 Sentence denotes The other assays cross reacted with one or more samples: the combined IgM/IgG Rapid Test IgM (Sol scientific®) showed cross-reaction with CMV IgM+ sample, ANF+ sample, RF+ sample and Tox IgM+ sample, the COVID-19 IgG/IgM RAPID TEST IgM (PRIMA PROFESSIONAL®) showed cross-reaction with EBV IgM+, the Diagnostic Kit for IgG/IgM Antibody to SARS-CoV-2 IgM (WIZ BIOTECH) showed cross-reaction with RF+ sera, the Anti-SARS-CoV-2 ELISA IgA (EUROIMMUN®) showed cross-reaction with CMV IgM+ sample and the Novel Coronavirus COVID-19 IgM (Epitope Diagnostics®) had a cross-reaction with one pre-pandemic sample.
T171 3083-3201 Sentence denotes In our institution a total of 145 patients were hospitalized with an in-house laboratory confirmed COVID-19 diagnosis.
T172 3202-3340 Sentence denotes In this group, the presence of SARS-CoV-2 was confirmed using RT-PCR on the first nasopharyngeal and/or throat swab in 132 patients (91%).
T173 3341-3436 Sentence denotes Another 4 patients were diagnosed with a second nasopharyngeal and 1 patient with an anal swab.
T174 3437-3495 Sentence denotes Next, 5 patients were found to be positive on BAL samples.
T175 3496-3549 Sentence denotes Three patients remained negative on repetitive swabs.
T176 3550-3703 Sentence denotes These patients were not eligible for a BAL sampling procedure or did not present with respiratory symptoms and as such serological testing was performed.
T177 3704-3795 Sentence denotes All 3 patients were found to be positive for IgG SARS-CoV-2 serology (Prima Professional®).
T178 3796-3995 Sentence denotes Given the high pre-test probability for SARS-Cov-2 in this prospective cohort and repetitive testing, the added diagnostic value of SARS-CoV-2 serology in providing a diagnosis in this cohort was 2%.